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ypertension, Heart
ailure, and Beta-Adrenergic
locking Drugs*
ichael B. Fowler, MB, FRCP, FACC
tanford, California
eta-adrenergic receptor blocking drugs have arguably pre-
ented or delayed more deaths in patients with established
eart disease that any other class of pharmaceutical agent
1). These drugs fundamentally alter the clinical course of
atients with heart failure and a reduced left ventricular
jection fraction, improving left ventricular performance,
eversing left ventricular remodeling, and reducing the risk
f hospitalization or dying (2). Beta-adrenergic receptor
locking drugs (beta-blockers) were also the first, and still
rguably one of the more powerful, interventions to improve
urvival when prescribed as long-term therapy after acute
yocardial infarction (3). The role of beta-blockers to
revent the development of heart failure is less clear. Some
gents have been shown to reduce reinfarction, one impor-
ant contributor to subsequent heart failure. Beta-blockers
ere included with the optimal therapy prescribed in the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) trial (4), the result
estifying to the efficacy of medical therapy for coronary
rtery disease. These drugs protect against acute myocardial
nfarction in patients undergoing noncardiac surgery (5), but
his indication has been associated with increased stroke
isk, especially in patients in whom sepsis or hypotension
eveloped (6). Even the presentation of ischemic heart
isease seems to be influenced by beta-blockers, with fewer
atients on these drugs experiencing acute myocardial
nfarction (7).
See page 1062
The American College of Cardiology/American Heart
ssociation guidelines for the treatment of heart failure
mphasize control of blood pressure as an important strat-
gy to prevent heart failure. This is an important issue
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Division of Cardiovascular Medicine, Stanford University School of
edicine, Stanford, California.ecause hypertension precedes heart failure in the majority
f patients who develop this devastating condition (8,9).
ypertension is especially significant in patients with heart
ailure and a preserved left ventricular ejection fraction.
nsulin resistance, diabetes, and obesity are also important
n the development of heart failure and are closely linked to
ypertension (10).
Introduced in the 1960s as drugs to treat angina, beta-
lockers were soon realized to be effective and, compared
ith many other available agents at that time, well tolerated
ntihypertensive agents. Based on the limited trials data
vailable beta-blockers were included as first-line therapy in
ational guidelines for the treatment of hypertension (11).
ost of the evidence for this recommendation came from
rials that compared thiazide-type diuretics and/or beta-
lockers to placebo or usual care. Reduced risk of stroke or
eart failure was the benefit most commonly reported. The
mpact on coronary artery disease events was modest, and at
he time was attributed to the short duration of the trials.
ubsequently the SHEP (Systolic Hypertension in the
lderly Program) trial (12), which evaluated chlorthalidone
n elderly hypertensive patients, did show a reduction in
ajor coronary events and a substantial reduction by 49% in
he risk of developing heart failure. The ALLHAT (Anti-
ypertensive and Lipid-Lowering Treatment to Prevent
eart Attack Trial) (13) study results suggested that most
f the benefits of treating hypertension were related to
owering blood pressure with little impact dependant on a
pecific drug class. All of the comparison therapies were
ound to be similar to chlorthalidone (again, perhaps sig-
ificantly, chosen to represent the thiazide diuretic class,
nd associated with the greatest reduction in blood pressure)
n preventing the primary composite coronary heart disease
nd point. Doxazosin, an alpha-blocker, was shown to be
he least effective in preventing heart failure, a secondary
nd point. Heart failure was also 38% more frequent in the
mlodipine group and 15% more frequent in the lisinopril
roup. Beta-blockers were not included in the randomized
rug classes but were included as one potential add-on
herapy. In the ANBP2 (Second Australian National Blood
ressure Study) trial (14), in which 6,085 hypertensive
atients were followed up for 4.1 years, hydrochlorothiazide
as associated with 15% more heart failure than enalapril.
iabetic hypertensive patients are at especially high risk
or developing heart failure and were shown to have 57%
ess risk of developing heart failure with more aggressive
lood pressure control in a UKPDS (UK Prospective
iabetes Study) trial (15). Interestingly, in this trial the
ore aggressive multiple agent regimens could be based on
tenolol or captopril.
The paper by Bangalore et al. (16) in this issue of the
ournal used meta-analysis to examine the role of beta-
lockers to prevent heart failure in patients being treated for
ypertension and to compare them with other classes of
ntihypertensive drugs. The Bangalore et al. (16) meta-
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Editorial Comment September 23, 2008:1073–5nalysis found that beta-adrenergic blocking drugs were as
ffective as any other class of agents in preventing heart
ailure. Heart failure was not the primary end point in any
f the individual trials of antihypertensive therapy examined
n this analysis, nor was there a uniform definition for the
evelopment of this syndrome. Another analysis has sug-
ested that calcium channel blockers may be inferior as
rst-line agents to prevent heart failure, but as the investi-
ators point out, this analysis may have been impacted
hough inclusion of comparison trials that included diuretics
ith beta-blockers. Based on this meta-analysis, beta-
drenergic blocking drugs are rightly included among the
gents used to prevent the development of heart failure.
lthough it is not possible to predict which complication of
ypertension may be inflicted on an individual patient,
ractitioners should be reassured that they can include
eta-blocking drugs as cardioprotective agents supporting
heir use in patients with pre-existing heart disease.
Both diuretics and beta-blockers are recognized to have
mportant limitations that argue against their routine use as
rst-line antihypertensive agents (11,17). An adverse effect
n glucose metabolism poses a significant disadvantage in a
herapy given to protect against the adverse cardiovascular
onsequences of hypertension. Both diuretics and beta-
lockers have been associated with the development of
iabetes (11,18). Meta-analysis has shown a 32% increased
isk of new-onset diabetes with beta-blockers in trials
omparing placebo or nondiuretic therapy. With diuretics,
he increased risk of diabetes was 35% compared with
lacebo or nonbeta-blocker antihypertensive agents (11). It
s conceivable that the adverse metabolic consequence of
hiazide diuretics may be less than that seen with conven-
ional beta-blockers. The use of chlorthalidone in particular
eems not to be associated with any diminution of benefit
13). The results of the ACCOMPLISH (Avoiding Car-
iovascular events through COMbination therapy in Pa-
ients Living with Systolic Hypertension) study do question
ur complacency regarding this adverse effect of all thiazides
19). Although this study design was criticized for being of
imited scientific relevance, the results, reported at the
merican College of Cardiology annual meeting this year,
howed fewer events in the group on the combination of an
ngiotensin-converting enzyme (ACE) inhibitor with am-
odipine compared with the group on an ACE inhibitor and
ydrochlorothiazide. These findings indicate the impor-
ance of considering drug combinations rather than extrap-
lating from the results based on choice of first-line therapy.
he results also suggest that different drugs within a class
ay not be equally effective. Beta-blockers should be rec-
gnized as having more heterogeneity within a drug class
han other agents. Beta-blockers vary in their affinity for
eta-1 and -2 receptors; some also block alpha receptors,
onferring vasodilator properties even to nonselective
gents. Some have intrinsic sympathomimetic activity.
hese different characteristics have been found to be signif-
cant in outcome trials after acute myocardial infarction (3) (nd heart failure (2). The adverse metabolic effect of
onvasodilating beta-blockers is likely to assume even
reater significance in hypertension when the therapy is
eing prescribed for long periods to prevent the vascular and
ardiac consequences of high blood pressure. Two compar-
son trials with atenolol, a lipophobic beta-1 selective agent,
ot only showed less stroke prevention but also more new
evelopment of diabetes compared with the patients ran-
omized, in one trial, to the angiotensin receptor blocking
ARB) drug lorsartan (20), and in the other, to the dihy-
ropyridine calcium channel blocking drug amlodipine (21).
subsequent meta-analysis, not confined to atenolol, re-
orted 16% more stroke with beta-blockers and contributed
o the recommendation that beta-blockers as a class should
o longer be chosen routinely as first-line agents to treat
ypertension (22). Whether this adverse effect is common to
ll beta-blocking drugs, or whether the absence of an
dverse impact on glucose metabolism as demonstrated
ith the vasodilating beta-blocking drug carvedilol in the
EMINI (Glycemic Effects in Diabetes Mellitus:
arvedilol-Metoprolol Comparison in Hypertensives) study
23) has a mitigating effect on stroke prevention has not
een established. The American Association of Clinical
ndocrinologists do advise in their guidelines (24) that
eta-blockers with vasodilating properties are preferable as
econd-line or third-line agents. But other factors not
elated to insulin resistance, such as a differential impact on
entral aortic pressure, may be of equal importance. A
andomized trial in hypertension is needed to determine
hether beta-adrenergic blocking drugs with vasodilator
roperties, especially if combined with an ACE inhibitor or
n ARB, would result in improved protection from all the
dverse outcomes associated with hypertension, including
troke and heart failure, than can be achieved with tradi-
ional beta-blocking drugs. Based on the available data and
n the absence of any other new outcomes trial, beta-
lockers cannot be recommended as routine first-line ther-
py to treat hypertension (16,21,25).
The majority of patients with hypertension will require
ore than one agent to achieve target blood pressure. The
mpact of beta-blockers when combined with other classes
f drugs, especially ACE inhibitors in patients with estab-
ished cardiac disease, support their use in hypertensive
atients who are not at target blood pressure. These patients
re especially likely to progress to heart failure. It is
onceivable that the combination of beta-blockers with
CE inhibitors or ARBs, shown to be beneficial after acute
yocardial infarction or in heart failure, irrespective of an
ffect on blood pressure, would also be advantageous at an
arlier stage of the disease even in the absence of hyperten-
ion. Given the importance of insulin resistance in the
evelopment of heart failure, it is reassuring that the
onventional nonvasodilating beta-blockers, the principal
gents evaluated in the meta-analysis by Bangalore et al.
16), were found to be effective in preventing heart failure.
o
a
b
a
t
d
a
d
p
t
i
d
e
c
q
o
a
s
n
o
a
t
t
t
u
c
R
D
o
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
K
1075JACC Vol. 52, No. 13, 2008 Fowler
September 23, 2008:1073–5 Editorial CommentTreatment of patients with hypertension should be based
n the outcomes observed in randomized trials or meta-
nalyses. Ultimately, drug choices in individual patients will
e determined by tolerability and response to specific agents,
nd especially by the need to manage concomitant condi-
ions. Despite the number of inexpensive well-tolerated
rugs, only one-half of patients with hypertension are
dequately treated. The tendency to demonize one class of
rugs, especially a drug class with profound benefits to
atients with established cardiac disease, can only contribute
o further therapeutic nihilism. Although it is becoming
ncreasingly apparent that differences do exist between
ifferent classes of antihypertensive agents, it is also appar-
nt that these differences, although important, are of trivial
onsequence compared with the adverse impact of inade-
uate treatment. Calcium-channel blockers were errone-
usly targeted in the 1990s (26). Thiazide diuretics, lauded
fter the findings of the ALLHAT study, are now under
crutiny after finding hydrochlorothiazide (given in combi-
ation with benazapril) was less effective in preventing adverse
utcomes than a combination benazapril/amlodipine prep-
ration. In an era when scientific discourse regarding drug
herapy is played out in the lay press, it is hardly surprising
hat patients do not persist with effective antihypertensive
herapy but turn instead to alternative medicines, blissfully
naware that the subsequent development of heart failure
ould have been prevented.
eprint requests and correspondence: Dr. Michael B. Fowler,
ivision of Cardiovascular Medicine, Stanford University School
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